Semantic Scholar uses AI to extract papers important to this topic.
Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small… Expand Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous… Expand Recent breakthroughs regarding gastrointestinal stromal tumors (GIST) and their pathogenesis have redefined diagnostic criteria… Expand Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in refractory/relapsed Philadelphia… Expand Inappropriate expression of the multidrug resistance (MDR1) gene encoding the P-glycoprotein (Pgp) has been frequently implicated… Expand The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable… Expand PURPOSE
Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet… Expand BACKGROUND
Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal… Expand BACKGROUND
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia… Expand This review discusses the development and uses of imatinib mesylate, a protein tyrosine kinase inhibitor useful in the treatment… Expand